Table 1 Demographic and clinical characteristics of patients with knee arthritis
Patients with knee arthritis | n = 114 (%) |
|---|---|
Gender | |
Female | 80 (70.2) |
Male | 34 (29.8) |
Mean age ± SD/ median (min-max) | 11.0 ± 4.3 / 11.6 (1–18) |
Category of JIA | |
Oligoarticular JIA | 92 (80.7) |
Polyarticular JIA | 18 (15.8) |
Enthesitis related arthritis | 2 (1.8) |
Psoriatic arthritis | 2 (1.8) |
Previous Intraarticular steroid application of the knee joint(-s) | 72/114 (63.1) |
Unilateral | 42/114 (36.8) |
Bilateral | 30/114 (26.3) |
ANA positivity | 97/112 (86.6) |
HLAB-27 positivity | 11/94 (11.7) |
RF positivity | 3/109 (2.8) |
Anti-CCP positivity | 3/63 (4.8) |
Clinical signs of arthritis | |
Palpable joint effusion | 107/110 (97.3) |
LOM | 75/102 (73.5) |
Pain | 83/111 (74.8) |
Swelling | 108/112 (96.4) |
Current medication use | 81/113 (71.7) |
Biologicals | 6/113 (5.3) |
Methotrexate | 36/113 (32) |
Systemic steroid | 6/113 (5.3) |
Other medications | 61/113 (54) |
Current eye involvement | 13/113 (11.5) |
Mean ± SD / median (min-max) | |
Parameters of disease activity | |
JADAS10 score | 12.6 ± 5.4 / 11.3 (3.0–30.0) |
Number of active joints | 2.9 ± 4.6 / 2.0 (1–45.0) |
VAS activity of patient | 4.6 ± 2.2 / 5.0 (0–9.0) |
VAS activity of physician | 4.9 ± 1.9 / 3 (1.0–10.0) |
Erythrocyte sedimentation ratio (mm/h) | 19.0 ± 18.7 / 11.5 (1.0–84.0) |
C-reactive Protein (mg/dL) | 1.3 ± 2.7 / 0.3 (0-23.7) |